title: Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
abstract: Cannabinoids act at two classical cannabinoid receptors (CB1 and CB2), a 7TM orphan receptor and the transmitter-gated channel transient receptor potential vanilloid type-1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator-activated receptors (PPARs, with three subtypes alpha, beta (delta) and gamma), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPAR alpha. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPAR alpha. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti-inflammatory properties mediated by PPAR alpha. Other endocannabinoids that activate PPAR alpha include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPAR gamma; anandamide and 2-arachidonoylglycerol have anti-inflammatory properties mediated by PPAR gamma. Similarly, ajulemic acid, a structural analogue of a metabolite of Delta(9)-tetrahydrocannabinol (THC), causes anti-inflammatory effects in vivo through PPAR gamma. THC also activates PPAR gamma, leading to a time-dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPAR gamma include N-arachidonoyl-dopamine, HU210, WIN55212-2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPAR delta. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro- and cardioprotective benefits as other PPAR alpha and PPAR gamma agonists? This review will summarize the published literature implicating cannabinoid-mediated PPAR effects and discuss the implications thereof.
authors: School of Biomedical Sciences, University of Notttingham, Queen's Medical Center, Nottingham, UK. saoirse.o'sullivan@nottingham.ac.uk
authors: S E
authors: SE
authors: O'Sullivan
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D008954:Models, Biological; D015394:Molecular Structure; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism
chemical_list: D002186:Cannabinoids; D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors
references: Int J Cancer. 2003 Mar 10;104(1):12-8
references: 12532414
references: Curr Opin Pharmacol. 2003 Apr;3(2):186-91
references: 12681242
references: J Clin Endocrinol Metab. 2006 Aug;91(8):3171-80
references: 16684820
references: Anal Biochem. 2005 Sep 1;344(1):8-15
references: 16038868
references: Eur J Pharmacol. 2007 Jul 2;566(1-3):117-9
references: 17434479
references: Am J Physiol Cell Physiol. 2005 Apr;288(4):C899-905
references: 15590897
references: Biochem Soc Trans. 2006 Dec;34(Pt 6):1095-7
references: 17073758
references: J Pharmacol Exp Ther. 2006 Aug;318(2):563-70
references: 16702440
references: Cell Mol Life Sci. 2007 Jan;64(2):219-29
references: 17187172
references: J Clin Invest. 2006 Mar;116(3):556-60
references: 16511587
references: Biochim Biophys Acta. 2007 Aug;1771(8):1094-107
references: 17459763
references: Trends Pharmacol Sci. 2004 Jun;25(6):331-6
references: 15165749
references: Diabetes. 2004 Feb;53 Suppl 1:S43-50
references: 14749265
references: Mol Pharmacol. 2003 May;63(5):983-92
references: 12695526
references: Eur J Pharmacol. 2005 Jul 11;517(3):174-81
references: 15987634
references: J Biol Chem. 2007 Jun 22;282(25):18625-33
references: 17462987
references: Mol Pharmacol. 2006 Jul;70(1):101-11
references: 16611855
references: J Biol Chem. 2004 Jul 2;279(27):27849-54
references: 15123613
references: Br J Pharmacol. 2000 Mar;129(5):823-34
references: 10696077
references: Cell Mol Life Sci. 2007 Jun;64(11):1403-18
references: 17447008
references: Nature. 2003 Sep 4;425(6953):90-3
references: 12955147
references: J Biol Chem. 2002 Jun 28;277(26):23278-86
references: 11956198
references: Neuroscience. 2004;123(1):131-45
references: 14667448
references: J Clin Invest. 2006 Mar;116(3):590-7
references: 16511591
references: Life Sci. 2006 Jan 2;78(6):549-63
references: 16109430
references: PPAR Res. 2007;2007:95974
references: 17389767
references: J Pharmacol Exp Ther. 2006 Apr;317(1):428-38
references: 16352700
references: Circ Res. 2007 May 25;100(10):1442-51
references: 17463321
references: Biochem Biophys Res Commun. 2005 Nov 25;337(3):824-31
references: 16213464
references: J Pharmacol Exp Ther. 2004 Nov;311(2):683-90
references: 15284281
references: Lancet. 2007 Feb 17;369(9561):555
references: 17307094
references: J Neurochem. 2005 May;93(4):984-91
references: 15857401
references: J Biol Chem. 2002 Nov 1;277(44):41925-30
references: 12200443
references: Expert Opin Investig Drugs. 2005 Jun;14(6):557-68
references: 16004588
references: Neuroscience. 2005;130(2):325-37
references: 15664689
references: Diabetes. 1997 Aug;46(8):1319-27
references: 9231657
references: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23
references: 9113987
references: Neuropharmacology. 2008 Jan;54(1):226-34
references: 17467748
references: Mol Pharmacol. 2005 Jan;67(1):15-9
references: 15465922
references: J Pharmacol Exp Ther. 2006 Dec;319(3):1051-61
references: 16997973
references: Curr Opin Pharmacol. 2006 Dec;6(6):606-14
references: 16973418
references: Biochem Biophys Res Commun. 2007 Mar 9;354(2):427-33
references: 17223076